Time-course entry page: Difference between revisions
From Wiki
Jump to navigationJump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
| ⚫ | |||
| ⚫ | |||
== Detailed page for each time course == |
|||
* aa |
|||
== Overview of the time-courses == |
== Overview of the time-courses == |
||
* Human |
* Human |
||
| Line 311: | Line 317: | ||
</table> |
</table> |
||
|} |
|} |
||
| ⚫ | |||
| ⚫ | |||
Revision as of 16:09, 20 September 2011
Relate material
- Time-courses kick-off presentation at the regular FANTOM5 teleconference call (September 15, 2011): FANTOM5_analysis_call#September_15th
Detailed page for each time course
- aa
Overview of the time-courses
- Human
| simple description | cell type | cell line | collaborator | experiment condition | number donors or replicates | number time points per donor or replicate |
| adipocyte differentiation | adipocyte | Peter Arner (Karolinska Institutet) | Adipocyte differentiation | 4 | 3 | |
| Aortic Smooth Muscle cells treatment with FGF2 | smooth muscle cell, vascular associated | Levon Khachigian (University of New South Wales) | Aortic smooth muscle cell response to fibroblast growth factor 2 | 3 | 10 | |
| Aortic Smooth Muscle cells treatment with IL1b | smooth muscle cell, vascular associated | Levon Khachigian (University of New South Wales) | Aortic smooth muscle cell response to interleukin 1b | 3 | 10 | |
| ES cells differentiated towards cardiomyocyte | Christine Mummery/Robert Passier | 3 | 12 | |||
| H9 Embryoid body cells after melanocytic induction | stem cell/ unclassifiable | H9 | Susan Zabierowski (Wistar Institute) | Human ES cell differentiation to melanocyte | 3 | 14 |
| H9 Embryonic Stem cell | stem cell | H9 | Susan Zabierowski (Wistar Institute) | Human ES cell differentiation to melanocyte | 3 | 1 |
| K562 erythroblastic leukemia line | erythroblast | K562 | Peter Klinken (Western Australian Institute of Medical Research) | K562 erythroblastic leukemia response to hemin | 3 | 18 |
| Lymphatic Endothelial cells | endothelial cell, lymphatic | Michael Detmar (Swiss Federal Institute of Technology, ETH Zurich) | Lymphatic Endothelial cells response to Vascular endothelial growth factor C | 3 | 16 | |
| MCF7 breast cancer cell line EFG1 treatment | mammary gland epithelial cell | MCF7 | Mariko Okada Hatakeyama (RIKEN RCAI) | MCF7 breast cancer cell line response to Epidermal Growth Factor 1 | 3 | 16 |
| MCF7 breast cancer cell line HRG treatment | mammary gland epithelial cell | MCF7 | Mariko Okada Hatakeyama (RIKEN RCAI) | MCF7 breast cancer cell line response to Heregulin | 3 | 16 |
| Melanocyte | melanocyte | Susan Zabierowski (Wistar Institute) | Human ES cell differentiation to melanocyte | 3 | 1 | |
| mesenchymal stem cells adipogenic induction | Peter Arner(Karolinska) | 3 | 17 | |||
| mesenchymal stem cells (adipose derived) untreated control replicate1 | SELECT CELL TYPE | Peter Arner(Karolinska) | 3 | 1 | ||
| Monocyte-derived macrophages mock infection | HMDM | primary | Baillie/Tomoiu/Fisher/Hume | MI | 4 | 2 |
| Monocyte-derived macrophages udorn influenza infection | HMDM | primary | Baillie/Tomoiu/Fisher/Hume | Ud | 4 | 4 |
| Monocyte-derived macrophages LPS treatment | macrophage | Kenneth Baillie (Roslin Institute) | Monocyte derived macrophages repsonse to LPS | 5 | 26 | |
| Saos-2 osteosarcoma cell line induction of calcification with ascorbate and BPG | osteoblast | Kim Summers (Roslin Institute) | Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification | 3 | 18 | |
| Saos-2 osteosarcoma cell line 0min untreated control | osteoblast | Saos-2 | Kim Summers (Roslin Institute) | Saos-2 osteosarcoma untreated control | 3 | 18 |
| UH-1 | Christine Mummery/Robert Passier | 1 | 1 | |||
| UH-2 | Christine Mummery/Robert Passier | 1 | 1 | |||
| UH-3 | Christine Mummery/Robert Passier | 1 | 1 | |||
- Mouse
| simple description | cell type | cell line | collaborator | experiment condition | number donors or replicates | number time points per donor or replicate |
| EBF KO HPCs induced to T cell | unclassifiable | Tomokatsu Ikawa (RCAI) | T cell differentiation | 3 | 15 | |
| J2E erythroblastic leukemia line treatment with erythropoietin | erythroblast | J2E | Peter Klinken (Western Australian Institute of Medical Research) | J2E erythroblastic leukemia response to erythropoietin | 3 | 16 |
| ST2 (Mesenchymal stem cells) cells medium change (without induction) | mesenchymal stem cell | ST2 | Yasushi Okazaki (Saitama medical college) | ST2 mesenchymal stem cell differentiation medium change untreated control | 3 | 10 |
| ST2 (Mesenchymal stem cells) cells adipogenic induction | mesenchymal stem cell | ST2 | Yasushi Okazaki (Saitama medical college) | ST2 mesenchymal stem cell differentiation to adipocytes | 3 | 15 |
| ST2 (Mesenchymal stem cells) cells osteogenic induction | mesenchymal stem cell | ST2 | Yasushi Okazaki (Saitama medical college) | ST2 mesenchymal stem cell differentiation to osteocytes | 3 | 15 |
| tracheal ciliated cells differentiation | Mitsuru Morimoto | 3 | 18 | |||
| trophoblast stem cell line B1 0 days after differentiation | Hirohiko Kodeki(RCAI) | 3 | 6 | |||
| TSt-4/DLL1 feeder cells | unclassifiable | Tomokatsu Ikawa (RCAI) | T cell differentiation | 3 | 1 | |
